Insights of Bangladeshi Doctors on Usage, Acceptance and Future Prospects of Vonomax (Vonoprazan)

Author(s): Dr. Faruque Ahmed, Mohammod Shafiqul Islam, Md. Muksidul Haque, Dr. Zayer Rashid, Dr. Mohaiminur Rahman, Md. Ahsanur Rahman, Md. Mustafizur Rahman

Introduction: Acid-related gastrointestinal disorders such as gastritis, peptic ulcer, and gastroesophageal reflux disease (GERD) are commonly encountered in clinical practice throughout Bangladesh. While proton pump inhibitors (PPIs) have long been the standard treatment, many physicians report limitations, including delayed symptom relief and variable efficacy. Vonoprazan, a potassium-competitive acid blocker, has emerged as a promising alternative due to its rapid onset, ensuring desired actions from the very first day, along with sustained acid suppression and a favorable safety profile.

Aim of the Study: This study aimed to explore the real-world usage, physician perceptions, and clinical experiences regarding Vonomax (vonoprazan) as a treatment for acid-related disorders among doctors in Bangladesh.

Methods: A cross-sectional survey was conducted among 500 practicing physicians from various specialties, including gastroenterology, internal medicine, and cardiology. The structured questionnaire collected information on prescribing habits, perceived effectiveness and safety, patient compliance, and dosage patterns. Data was compiled and analyzed to identify trends in clinical practice and physician preferences.

Results: Out of 500 surveyed physicians, 72% reported prescribing Vonomax as a first-line treatment for acid-related gastrointestinal complications, while 25% used it frequently in clinical practice. The vast majority (99%) considered it effective, with 87% rating it as highly effective. Only 1.4% of doctors reported mild side effects such as nausea, fast gastric emptying, or headache, while 98.6% observed no adverse reactions. Physicians commonly used Vonomax for GERD, gastric ulcers, and Helicobacter pylori eradication, adhering to standard dosing protocols. Compared to traditional PPIs, respondents favored Vonomax for its faster onset of action, improved patient compliance, consistent efficacy, and better safety profile across a wide range of patients, including those with renal or hepatic impairment.

Conclusion: The findings suggest a strong and growing preference for Vonomax among physicians in Bangladesh, supported by its rapid symptom relief, excellent tolerability, and practical dosing flexibility. These insights highlight the evolving landscape of acid-suppressive therapy and support broader integration of vonoprazan into clinical practice.